Literature DB >> 6834271

Avoidance of "first-pass" elimination of rectally administered lidocaine in relation to the site of absorption in rats.

L G de Leede, A G de Boer, C P Roozen, D D Breimer.   

Abstract

The extent of "first-pass" elimination of lidocaine in relation to the site of absorption in the rectum of rats was investigated. Male Wistar rats received lidocaine orally, i.v. or rectally at 4, 2, 1 and at about 0.2 cm from the anus. In all cases 5.0 mg of a tritium-labeled lidocaine solution was administered by zero-order infusion into the rectum. In blood, unchanged lidocaine and urine and feces total radioactivity were measured. Lidocaine was absorbed almost completely in all cases as assessed relative to i.v. administration. The average elimination half-life was about the same for all routes of administration (approximately 27 min). Systemic availability of lidocaine when given by the oral route was 16%; a similar value was found after rectal administration at 4 cm distance from the anus. At 2 cm distance from the anus the mean systemic availability was 21%, at 1 cm, 45% and as closely as possible to the anus, 72%. It is concluded that the degree of avoidance of first-pass elimination of rectally administered lidocaine is very much dependent on the site of drug administration. When the drug is absorbed very closely to the anus, little first-pass elimination occurs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6834271

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

1.  Absorption enhancement of rectally infused insulin by sodium tauro-24,25-dihydrofusidate (STDHF) in rats.

Authors:  E J van Hoogdalem; C D Heijligers-Feijen; J C Verhoef; A G de Boer; D D Breimer
Journal:  Pharm Res       Date:  1990-02       Impact factor: 4.200

2.  Absorption of 2',3'-dideoxyinosine from lower gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and rectum.

Authors:  S L Bramer; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

3.  Biologic activity of 5'-deoxy-5-fluorouridine by rectal administration.

Authors:  S L Bramer; L C Gunnarsson; J L Au
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

4.  Absorption of 5'-deoxy-5-fluorouridine from colon.

Authors:  J L Au; L C Gunnarsson
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

5.  Rectal absorption enhancement of des-enkephalin-gamma-endorphin (DE gamma E) by medium-chain glycerides and EDTA in conscious rats.

Authors:  E J van Hoogdalem; C D Heijligers-Feijen; A G de Boer; J C Verhoef; D D Breimer
Journal:  Pharm Res       Date:  1989-01       Impact factor: 4.200

6.  Avoidance of "first-pass" elimination of rectally administered propranolol in relation to the site of absorption in rats.

Authors:  L G de Leede; A G de Boer; J P Havermans; D D Breimer
Journal:  Pharm Res       Date:  1984-07       Impact factor: 4.200

7.  Site specific rectal drug administration in man with an osmotic system: influence on "first-pass" elimination of lidocaine.

Authors:  L G de Leede; A G de Boer; C D Feijen; D D Breimer
Journal:  Pharm Res       Date:  1984-05       Impact factor: 4.200

8.  Bupivacaine administered intrathecally versus rectally in the management of intractable rectal cancer pain in palliative care.

Authors:  Iwona Zaporowska-Stachowiak; Grzegorz Kowalski; Jacek Luczak; Katarzyna Kosicka; Aleksandra Kotlinska-Lemieszek; Maciej Sopata; Franciszek Główka
Journal:  Onco Targets Ther       Date:  2014-10-06       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.